Jean-Pierre Garnier elected as Chairman of Actelion's Board of Directors
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Jean-Pierre Garnier elected as Chairman of Actelion's Board of Directors
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 27 September 2011 - Actelion Ltd (SIX: ATLN)
announced today that Jean-Pierre Garnier has become Chairman of the Board of
Directors of the Swiss biopharmaceutical company. The Board of Directors elected
him at their meeting today, 27 September 2011. In order to ensure a smooth
transition, Robert Cawthorn, who has been Chairman since the inception of the
company, will stay on the Board as planned until the 2012 Annual General
Meeting.
Robert Cawthorn said: "I am grateful for the opportunity I was given to assist
in building a company that has already achieved so much for patients,
shareholders and employees world-wide. My fellow Board members and I are
delighted that Jean-Pierre Garnier, a highly experienced and very successful
leader with an unparalleled career in the healthcare industry, will now guide
Actelion into the next phase of the company's development. Since joining the
Board, Jean-Pierre has been very active in talking to Actelion's key people and
understanding the company's opportunities and challenges. We are now entering a
new planning cycle and he will be able to oversee this process and its
implementation as Chairman from the start."
Dr. Jean-Pierre Garnier said: "I am extremely proud to have been nominated as
Chairman of the Board of Actelion. I'm very impressed with the company's track
record and its position today as Europe's largest biopharmaceutical company.
Since joining the company this spring, I have become even more convinced of
Actelion's capacity to translate superior drug discovery into meaningful
therapeutic solutions and long-term business success. I look forward to guiding
the company in the next phase of its growth together with my fellow Board
members, management and all the Actelion employees."
Jean-Paul Clozel, co-founder and CEO of Actelion, said: "I would like to thank
Rob Cawthorn for his outstanding achievements for Actelion. As the Chairman of a
unique and very professional Board, he helped a small start-up become Europe's
largest biopharmaceutical company. I am very glad that Jean-Pierre Garnier, one
of the world's most renowned pharma managers, has agreed to become his
successor. He is the right person to lead Actelion into the next stage of the
company's development."
Notes to the editor
About Jean-Pierre Garnier
Jean-Pierre Garnier was elected to Actelion's Board of Directors at the
company's Annual General Meeting on 5 May 2011.
From 2001 to 2008, Jean-Pierre Garnier was the first Chief Executive Officer of
GlaxoSmithKline. He assumed this role on the merger of SmithKline Beecham and
Glaxo Wellcome. He joined SmithKline Beecham in 1990 as President of its
pharmaceutical business in North America and served as Chairman, Pharmaceuticals
from 1994 until his appointment as Chief Operating Officer in 1995. He was
elected to the company's Board of Directors in 1992. He became Chief Executive
Officer of SmithKline Beecham in April 2000.
Prior to SmithKline Beecham, Jean-Pierre Garnier served as President of
Schering-Plough's US business. During his 15 years at Schering, he held various
management positions, including General Manager of several overseas
subsidiaries.
From 2008 to 2010, Jean-Pierre Garnier was CEO of Pierre Fabre Labs, a
pharmaceutical and cosmetics company located in France
He serves on the Boards of Directors of the United Technologies Corporation and
Renault S.A. He is Chairman of the US biopharmaceutical company NormOxys
(biotechnology), serves on the Board of the French biotech firm Cerenis and acts
as operating partner at Advent International, a global private equity firm.
Dr. Garnier's accomplishments have been recognized with many prestigious
appointments and awards. In 2001, he was presented with the Marco Polo Award for
GlaxoSmithKline's commitment to China. In 2005, he was presented with the Global
Business Leadership Award from Stanford Business School. In July 2007, he was
appointed to the UK Prime Minister's Business Advisory Council. In 2007/2008 he
was a strategic advisor to the investment fund Dubai International Capital. In
1997, Jean-Pierre Garnier received the Chevalier de la Légion d'Honneur and in
January 2008, he was promoted to Officier de Légion d'Honneur. In May 2009,
Jean-Pierre Garnier was appointed as "Knight Commander of the British Empire".
Jean-Pierre Garnier holds a PhD in pharmacology and an MSc in pharmaceutical
science from the University Louis Pasteur of Strasbourg in France. As a
Fulbright Scholar, he earned an MBA at Stanford University, California, in 1974.
###
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,500 employees focus on the
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker
symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index
SMI®).
For further information please contact:
Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
ISIN: CH0010532478;
Press Release PDF:
http://hugin.info/131801/R/1550274/477236.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
[HUG#1550274]
Unternehmensinformation / Kurzprofil:
Datum: 27.09.2011 - 17:45 Uhr
Sprache: Deutsch
News-ID 69701
Anzahl Zeichen: 7775
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 273 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Jean-Pierre Garnier elected as Chairman of Actelion's Board of Directors"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
